AbbVie Inc. $ABBV Shares Sold by Banque Pictet & Cie SA

Key Points

• Banque Pictet & Cie SA reduced its AbbVie stake by 8.3% in the third quarter, selling 33,788 shares and retaining 375,536 shares valued at approximately $98.2 million. Institutional investors and hedge funds own 70.23% of AbbVie.
• Analysts remain broadly positive, with 23 Buy ratings and an average “Moderate Buy” consensus; the average price target is $277.18, while JPMorgan raised its target to $300.
• AbbVie reported quarterly earnings and revenue above estimates and announced a quarterly dividend of $1.73 per share, equivalent to a $6.92 annualized payout and a 2.4% yield.

Banque Pictet & Cie SA cut its stake in AbbVie Inc. (NYSE:ABBV - Free Report) by 8.3% in the third quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 375,536 shares of the company's stock after selling 33,788 shares during the period. AbbVie accounts for about 0.7% of Banque Pictet & Cie SA's portfolio, making the stock its 24th largest position. Banque Pictet & Cie SA's holdings in AbbVie were worth $98,236,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other institutional investors also recently bought and sold shares of the stock. James T. Borello RIA lifted its position in AbbVie by 3.5% during the 3rd quarter. James T. Borello RIA now owns 1,192 shares of the company's stock worth $312,000 after acquiring an additional 40 shares during the period. ACT Advisors LLC. increased its holdings in AbbVie by 2.5% in the 2nd quarter. ACT Advisors LLC. now owns 1,688 shares of the company's stock worth $425,000 after buying an additional 41 shares during the period. Willner & Heller LLC raised its position in AbbVie by 0.7% during the 2nd quarter. Willner & Heller LLC now owns 5,852 shares of the company's stock worth $1,472,000 after buying an additional 43 shares during the last quarter. B.O.S.S. Retirement Advisors LLC raised its position in AbbVie by 3.1% during the 2nd quarter. B.O.S.S. Retirement Advisors LLC now owns 1,427 shares of the company's stock worth $359,000 after buying an additional 43 shares during the last quarter. Finally, Fielder Capital Group LLC raised its position in AbbVie by 1.7% during the 2nd quarter. Fielder Capital Group LLC now owns 2,532 shares of the company's stock worth $637,000 after buying an additional 43 shares during the last quarter. 70.23% of the stock is currently owned by institutional investors and hedge funds.

Analysts Set New Price Targets

Several analysts have recently commented on the stock. BNP Paribas Exane upped their price objective on shares of AbbVie from $218.00 to $247.00 and gave the company a "neutral" rating in a report on Tuesday, August 11th. Oppenheimer boosted their price target on AbbVie from $244.00 to $258.00 and gave the company a "neutral" rating in a report on Monday, August 3rd. Bank of America restated a "buy" rating on shares of AbbVie in a research report on Tuesday, September 8th. Weiss Ratings raised shares of AbbVie from a "buy (b-)" rating to a "buy (b)" rating in a research note on Thursday, October 8th. Finally, JPMorgan Chase & Co. raised their price objective on shares of AbbVie from $285.00 to $300.00 and gave the stock an "overweight" rating in a research note on Thursday, October 8th. One research analyst has rated the stock with a Strong Buy rating, twenty-three have given a Buy rating and six have issued a Hold rating to the company's stock. According to data from MarketBeat, the company has an average rating of "Moderate Buy" and an average target price of $277.18.

AbbVie Price Performance

ABBV stock opened at $285.32 on Friday. The business has a 50 day simple moving average of $262.74 and a 200-day simple moving average of $239.22. The firm has a market capitalization of $504.10 billion, a PE ratio of 80.60, a price-to-earnings-growth ratio of 1.29 and a beta of 0.24. AbbVie Inc. has a 1 year low of $190.75 and a 1 year high of $291.40.

AbbVie (NYSE:ABBV - Get Free Report) last announced its quarterly earnings data on Friday, July 31st. The company reported $3.65 EPS for the quarter, topping analysts' consensus estimates of $3.61 by $0.04. The firm had revenue of $16.99 billion for the quarter, compared to the consensus estimate of $16.80 billion. AbbVie had a negative return on equity of 422.07% and a net margin of 9.80%. The firm's revenue was up 10.2% compared to the same quarter last year. During the same quarter last year, the business posted $2.97 earnings per share. AbbVie has set its Q3 2026 guidance at 3.840-3.880 EPS. On average, equities research analysts expect that AbbVie Inc. will post 13.94 EPS for the current year.

AbbVie Announces Dividend

The company also recently announced a quarterly dividend, which will be paid on Monday, November 16th. Shareholders of record on Thursday, October 15th will be paid a dividend of $1.73 per share. The ex-dividend date of this dividend is Thursday, October 15th. This represents a $6.92 dividend on an annualized basis and a yield of 2.4%. AbbVie's payout ratio is 195.48%.

More AbbVie News

Here are the key news stories impacting AbbVie this week:

• Positive Sentiment: Positive Phase 3 cancer-trial results provided the most important company-specific catalyst. AbbVie and Genmab reported that epcoritamab plus R-CHOP significantly reduced the risk of disease progression or death in newly diagnosed diffuse large B-cell lymphoma, strengthening AbbVie’s oncology pipeline and potential long-term growth. What Does AbbVie (ABBV) 51% DLBCL Risk Reduction Mean For Its Oncology Push?
• Positive Sentiment: Analyst and options-market confidence remains favorable. Erste Group Bank issued a positive earnings outlook, Royal Bank of Canada reaffirmed its Outperform rating, and traders purchased an unusually high volume of ABBV call options—signals of bullish expectations ahead of results. Erste Group Bank Issues Positive Outlook for AbbVie Earnings
• Positive Sentiment: Investors continue to view AbbVie as attractively valued for a large-cap pharmaceutical company. Coverage highlights a forward P/E near 16.4, strong year-to-date performance, a durable dividend, and newer medicines growing fast enough to offset declining Humira revenue. AbbVie is Outperforming the Market this Year So Far. Is Its 16.4x Valuation Attractive?
• Positive Sentiment: Sector rotation is helping the stock. Investors have been shifting toward defensive pharmaceutical companies as technology stocks weaken, pushing major drugmakers close to record highs. Big Pharma Stocks Close Near All-Time Highs
• Neutral Sentiment: Investors are now looking ahead to AbbVie’s third-quarter earnings report, scheduled for October 30. The results and updated guidance will test whether recent pipeline momentum and newer-drug growth justify the stock’s rally. AbbVie’s Q3 2026 Earnings: What to Expect
• Negative Sentiment: The primary risk remains the transition away from established blockbusters. AbbVie must prove that newer medicines can sustain earnings as mature products face competition, while its trailing valuation appears elevated despite a more reasonable forward multiple. AbbVie vs. Merck: Which Pharma Stock Offers Better Value?

Insiders Place Their Bets

In other AbbVie news, EVP Nicholas Donoghoe sold 32,710 shares of the business's stock in a transaction dated Friday, August 14th. The shares were sold at an average price of $250.00, for a total value of $8,177,500.00. Following the transaction, the executive vice president directly owned 74,430 shares in the company, valued at $18,607,500. The trade was a 30.53% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website. 0.06% of the stock is owned by insiders.

AbbVie Profile

AbbVie Inc is a global biopharmaceutical company that develops, manufactures and markets medicines for a range of serious and chronic health conditions. Its portfolio spans immunology, oncology, neuroscience, eye care, aesthetics, gastroenterology and women's health.

The company's products include the immunology medicines Skyrizi and Rinvoq; neuroscience treatments such as Vraylar, Ubrelvy and Qulipta; and oncology medicines including Imbruvica and Venclexta. AbbVie also markets Botox Cosmetic and Botox Therapeutic, as well as other products for aesthetics, eye care and specialty care.

AbbVie was established in 2013 as an independent, publicly traded company following its separation from Abbott Laboratories.

Want to see what other hedge funds are holding ABBV? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for AbbVie Inc. (NYSE:ABBV - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.